牛唐2021-03-31 09:44
$灿菲特生物制药(CANF)$ 的药物Piclidenoson和Namodenoson在现有的六份分销协议中,剩余的潜在里程碑付款高达约1.3亿美元,外加两位数的净销售额分成。$新泰医药(MDGL)$ $泰格医药(SZ300347)$查看全文
$Can-Fite Biopharma Ltd Sponsored ADR (Israel)(CANF)$ 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] Filed: 2018-10-25 AccNo: 0001213900-18-014437 Size: 27 KB 网页链接
$Can-Fite Biopharma Ltd Sponsored ADR (Israel)(CANF)$ 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] Filed: 2018-10-18 AccNo: 0001213900-18-014070 Size: 24 KB 网页链接
$Can-Fite Biopharma Ltd Sponsored ADR (Israel)(CANF)$ S-8 - Securities to be offered to employees in employee benefit plans Filed: 2018-10-09 AccNo: 0001213900-18-013702 Size: 171 KB 网页链接
$Can-Fite Biopharma Ltd Sponsored ADR (Israel)(CANF)$ EFFECT - Notice of Effectiveness Filed: 2018-09-13 AccNo: 9999999995-18-002353 Size: 1 KB 网页链接
$Can-Fite Biopharma Ltd Sponsored ADR (Israel)(CANF)$ 424B3 - Prospectus [Rule 424(b)(3)] Filed: 2018-09-13 AccNo: 0001213900-18-012495 Size: 341 KB 网页链接
$Can-Fite Biopharma Ltd Sponsored ADR (Israel)(CANF)$ 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] Filed: 2018-09-12 AccNo: 0001213900-18-012393 Size: 27 KB 网页链接
$Can-Fite Biopharma Ltd Sponsored ADR (Israel)(CANF)$ EFFECT - Notice of Effectiveness Filed: 2018-09-10 AccNo: 9999999995-18-002317 Size: 1 KB 网页链接
$Can-Fite Biopharma Ltd Sponsored ADR (Israel)(CANF)$ 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] Filed: 2018-09-04 AccNo: 0001213900-18-012043 Size: 27 KB 网页链接
$Can-Fite Biopharma Ltd Sponsored ADR (Israel)(CANF)$ POS AM - Post-Effective amendments for registration statement Filed: 2018-08-31 AccNo: 0001213900-18-012001 Size: 589 KB 网页链接
$Can-Fite Biopharma Ltd Sponsored ADR (Israel)(CANF)$ F-1/A [Amend] - Registration statement for certain foreign private issuers Filed: 2018-08-31 AccNo: 0001213900-18-012000 Size: 433 KB 网页链接